ZD6474 Ức Chế Các Isoform RET Gây Ung Thư Trong Mô Hình Drosophila Cho Các Hội Chứng U Tái Sinh Nội Tiết Đa Nguồn Loại 2 Và Carcinoma Tuyến Giáp Nhú
Tóm tắt
Từ khóa
Tài liệu tham khảo
Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. RET: normal and abnormal functions. Endocrinology 2004; 145: 5448–51.
Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL. A Drosophila model of multiple endocrine neoplasia type 2. Genetics. In press 2005.
Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284–90.
Huen DS, Elsdon M, Ponder BA. The Drosophila Ret gene is transcribed in multiple alternatively spliced forms. Mol Gen Genet 2000; 264: 335–40.
Hahn M, Bishop J. Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons. Proc Natl Acad Sci U S A 2001; 98: 1053–8.
Moses K, Rubin GM. Glass encodes a site-specific DNA-binding protein that is regulated in response to positional signals in the developing Drosophila eye. Genes Dev 1991; 5: 583–93.
Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784–93.
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–55.
McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3: 1041–8.
Fortini ME, Simon MA, Rubin GM. Signalling by the sevenless protein tyrosine kinase is mimicked by Ras1 activation [see comments]. Nature 1992; 355: 559–61.
Dickson B, Sprenger F, Morrison D, Hafen E. Raf functions downstream of Ras1 in the sevenless signal transduction pathway. Nature 1992; 360: 600–3.
Baker NE, Rubin GM. Effect on eye development of dominant mutations in Drosophila homologue of the EGF receptor. Nature 1989; 340: 150–3.
Lesokhin AM, Yu SY, Katz J, Baker NE. Several levels of EGF receptor signaling during photoreceptor specification in wild-type, Ellipse, and null mutant Drosophila. Dev Biol 1999; 205: 129–44.
Spencer SA, Powell PA, Miller DT, Cagan RL. Regulation of EGF receptor signaling establishes pattern across the developing Drosophila retina. Development 1998; 125: 4777–90.
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7.
Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054–8.
Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228–34.
Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6: 3319–26.
Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004; 64: 109–18; discussion 119–21.
Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004; 64: 2475–92.